NASDAQ 100 % ()
FTSE 100 % ()
DOLLAR INDEX % ()
BTC/USD % ()
EUR/USD % ()
GBP/USD % ()
GOLD % ()
SILVER % ()
CRUDE OIL % ()

AMGN

Amgen Inc. Nasdaq Global Select
$256
Open: $253.11 High: $255.23 Low: $249.52 Close: $252.92
Range: 2021-01-21 - 2021-01-22
Volume: 3,502,861
Market: Closed
Powered by Finage Stock APIDelayed data
AMGN
Amgen Inc. One Amgen Center Drive Thousand Oaks CA, 91320-1799 http://www.amgen.com
Amgen Inc is a U.S. based biotechnology company, with historical expertise in renal disease and cancer supportive care products. The firm discovers, develops, manufactures and delivers human therapeutics.
  • CEO: Robert A. Bradway
  • Employees: 20,800
  • Sector: Healthcare
  • Industry: Biotechnology
AMGN News
Latest news about the AMGN
  • 10 Blue Chip Dividend Stocks Hedge Funds Are Buying

    In this article, we presented the 10 blue-chip dividend stocks hedge funds are buying. Click to skip ahead and see 5 Blue Chip Dividend Stocks Hedge Funds are Buying. 2020 was one of the worst years for dividend and dividend growth stocks as pandemic and economic meltdown have strongly impacted cash flow generation of dividend-paying […]

    View More →
  • The Week Ahead In Biotech (Jan 24-30): J&J, Lilly to Kickstart Big Pharma Earnings, Amgen FDA Decision and More

    Biopharma stocks advanced yet again in the week ended Jan. 22, with the change of guard at the White House generating broader market strength.Eli Lilly And Co (NYSE: LLY) was the standout biopharma stock of the week, as it set fresh 52-week highs in all four sessions of the truncated week, the catalysts being an oncology licensing deal with Merus NV (NASDAQ: MRUS), an analyst upgrade and a positive readout for its COVID-19 antibody treatment candidate.News flow on licensing deals and follow-on offerings abounded.The Food and Drug Administration approved two key drugs during the week -- Merck & Co., Inc.'s (NYSE: MRK) heart failure drug and a long-acting, injectable combo treatment option for HIV from ViiV Healthcare, a venture established by GlaxoSmithKline plc (NYSE: GSK) and Pfizer Inc. (NYSE: PFE).Aurinia Pharmaceuticals Inc's (NASDAQ: AUPH) voclosporin in combination with a background immunosuppressive therapy regimen was also approved by the agency to treat adult patients with active lupus nephritis.Here are the key catalysts for the unfolding week:Conferences: The International Association for the study of Lung Cancer, or IASLC, World Conference on Lung Cancer (virtual event): Jan. 28-31PDUFA Dates: The FDA is scheduled to rule on Amgen, Inc.'s (NASDAQ: AMGN) sBLA for Nplate, a protein that raises and sustains platelet counts, as a treatment option for hematopoietic subsyndrome of acute radiation syndrome. The decision is due Thursday, Jan. 28.Related Link: The Gilead, Galapagos Pipeline Opportunities That Are Turning Morgan Stanley Bullish Regulatory Filings: Axsome Therapeutics Inc (NASDAQ: AXSM) expects to file this month a new drug application for its AXS-05 treatment of mild depressive disorder.Clinical Readouts: Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) is scheduled to host a virtual event on Tuesday, Jan. 26, from 8 a.m. to 10 a.m. to provide an update on its ongoing exploratory Phase 2 study and genetic sequencing efforts. The company will present data for setmelanotide in individuals living with heterozygous obesity due to genetic variants in one of two alleles of the POMC, PCSK1 or LEPR gene, as well as SRC1 and SH2B1 deficiency obesities. It will also provide an update on data from its sequencing efforts, which now includes samples from about 37,500 people with severe obesity.Zymeworks Inc (NYSE: ZYME) is due to present a clinical progress update for ZW49, which is being evaluated in a Phase 1 clinical trial as a treatment for patients with locally advanced or metastatic HER2-expressing cancers. The presentation is scheduled for Wednesday, Jan. 27, at 4:30 p.m.January Readouts Johnson & Johnson (NYSE: JNJ): interim results of a Phase 3 clinical trial of its experimental COVID-19 vaccine, JNJ-78436735GlaxoSmithKline plc (NYSE: GSK)/Vir Biotechnology Inc (NASDAQ: VIR): initial results from the Phase 3 trial of COVID-19 antibody treatment candidate VIR-7831IASLC World Conference on Lung Cancer Presentations View more earnings on IBBAmgen: Phase 2 data from the CodeBreaK 100 clinical study, evaluating investigational sotorasib in patients with KRAS G12C-mutated advanced non-small cell lung cancer, or NSCLC, (Friday, Jan. 2), and an oral presentation of updated Phase 1 data from AMG 757 in small cell lung cancerEarnings: Tuesday Johnson & Johnson (NYSE: JNJ) (before the market open) Varian Medical Systems, Inc. (NYSE: VAR) (after the close)Wednesday Abbott Laboratories (NYSE: ABT) (before the market open) Edwards Lifesciences Corp (NYSE: EW)(after the close) Hologic, Inc. (NASDAQ: HOLX) (after the close) Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (after the close)Thursday ABIOMED, Inc. (NASDAQ: ABMD) (before the market open) ResMed Inc. (NYSE: RMD) (after the close)Friday Lilly (before the market open)IPOs Raritan, New Jersey-based Ortho Clinical Diagnostics Holdings plc has filed to offer 70 million shares in an initial public offering, expected to be priced between $20 and $23. The pure-play in vitro diagnostics company has applied for listing the shares on the Nasdaq under the ticker symbol OCDX.Related Link: Pfizer-BioNTech Vaccine Found Effective Against New Coronavirus Strain In Lab Study See more from Benzinga * Click here for options trades from Benzinga * The Daily Biotech Pulse: Fluidigm's Saliva-Based COVID Test Approved In Europe, China Backs Amarin's Vascepa * The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces 0M Follow-On Offering, Boston Scientific Goes Shopping(C) 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    View More →
  • Merck's (MRK) Heart Failure Drug Vericiguat Gets FDA Nod

    Merck (MRK)/Bayer's (BAYRY) vericiguat gets FDA approval for symptomatic chronic heart failure and reduced ejection fraction

    View More →
  • Why Amgen (AMGN) Could Beat Earnings Estimates Again

    Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

    View More →
  • AMGN Stock: A Look At A Bullish Risk Reversal Option Trade

    Amgen (AMGN) stock has recently put in a series of higher highs and higher lows while the 21-day and 50-day moving averages have started to turn upward. Bullish traders wanting to take some upside exposure can do so via an options trade called a risk reversal. Risk reversals are bullish trades that involve selling an out-of-the-money put and using the...

    View More →
  • Barron’s Investing Experts See ‘Low-Level Civil War,’ Hyper Stimulus, and Risks That Haven’t Yet Materialized for the Stock Market

    The 10 investment pros on the Barron’s Roundtable see the U.S. economy growing 4% to 6% this year as Covid is defeated. But lofty valuations could limit the market’s gains. Plus, 9 picks from Bill Priest and Meryl Witmer

    View More →
  • Dow Jones Lower On Biden's $2 Trillion Stimulus Plan; U.S. Retail Sales Disappoint

    The Dow Jones Industrial Average traded modestly lower in today's stock market but the major indexes did come off their lows of the day.

    View More →
  • CORRECTED-Health data firm Target RWE buys NoviSci in Amgen-backed deal

    Target RWE, a privately held company that evaluates the use of drugs in patients in hospitals and other healthcare settings, told Reuters on Thursday it is acquiring peer NoviSci Inc with the backing of the latter's investor Amgen Inc. Amgen, a U.S. drugmaker, made a new investment in the combined company, joining Target RWE owners Norwest Venture Partners and 22C Capital.

    View More →
  • What Kind Of Shareholders Own Amgen Inc. (NASDAQ:AMGN)?

    Every investor in Amgen Inc. ( NASDAQ:AMGN ) should be aware of the most powerful shareholder groups. Large companies...

    View More →
  • 3 Top Biotech Picks for January

    Biotech stocks were huge winners for investors last year, with some seeing 1,000% gains. If you're looking for a stock in this sector to add to your portfolio, Amgen (NASDAQ: AMGN), Trillium Therapeutics (NASDAQ: TRIL), and Illumina (NASDAQ: ILMN) are solid biotech choices for this month. Amgen, founded in 1980, is one of the older, larger biotech companies in the world.

    View More →
  • The Daily Biotech Pulse: Bausch Health Issues Positive Pre-Announcement, Acorda Streamlines Operations

    Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 12) * AbbVie Inc (NYSE: ABBV) * AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) * Aldeyra Therapeutics Inc (NASDAQ: ALDX) * Alkermes Plc (NASDAQ: ALKS) * AtriCure Inc. (NASDAQ: ATRC) * Bioanalytical Systems, Inc. (NASDAQ: BASI) * BIOLASE Inc (NASDAQ: BIOL) (announced an agreement to expand laser adoption and hands-on training programs in targeted geographies) * CareDx Inc (NASDAQ: CDNA) * Celsius Holdings, Inc. (NASDAQ: CELH) * DermTech Inc (NASDAQ: DMTK) * Dyne Therapeutics Inc (NASDAQ: DYN) * Edap Tms SA (NASDAQ: EDAP) * Evelo Biosciences Inc (NASDAQ: EVLO) * EXACT Sciences Corporation (NASDAQ: EXAS) * Eyenovia Inc (NASDAQ: EYEN) * Genetron Holdings Ltd - ADR (NASDAQ: GTH) * Guardant Health Inc (NASDAQ: GH) (reacted to presentation at the JPMorgan Healthcare Conference) * Intra-Cellular Therapies Inc (NASDAQ: ITCI) * Kaleido Biosciences Inc (NASDAQ: KLDO) * Laboratory Corp. of America Holdings (NYSE: LH) * Merus NV (NASDAQ: MRUS) (announced presentation of Phase 1 data for MCLA-158 in metastatic colorectal cancer) * OncoSec Medical Inc (NASDAQ: ONCS) * Pacira Biosciences Inc (NASDAQ: PCRX) * PRA Health Sciences Inc (NASDAQ: PRAH) * Provention Bio Inc (NASDAQ: PRVB) * SAGE Therapeutics Inc (NASDAQ: SAGE) * Supernus Pharmaceuticals Inc (NASDAQ: SUPN) * Syneos Health Inc (NASDAQ: SYNH) * Travere Therapeutics Inc (NASDAQ: TVTX) * Vericel Corp (NASDAQ: VCEL) * X T L Biopharmaceuticals Ltd (NASDAQ: XTLB) * Zai Lab Ltd - ADR (NASDAQ: ZLAB)Down In The Dumps (Biotech Stocks Hitting 52-week Lows Jan. 12) * Fusion Pharmaceuticals Inc (NASDAQ: FUSN) * Lexaria Bioscience Corp. (LXRP) (the company's shares uplisted to Nasdaq and it also announced a $9.6 million public offering) * Viveve Medical Inc (NASDAQ: VIVE)Stocks In Focus Acorda to Sell Parkinson's Disease Drug Manufacturing Facility, Reduce 16% of Workforce Acorda Therapeutics Inc (NASDAQ: ACOR) announced a definitive agreement to sell its Inbrija manufacturing operations in Chelsea, Massachusetts to Catalent Inc (NYSE: CTLT) for $80 million in cash.In connection with the sale, Acorda and Catalent have entered into a long-term global supply agreement under which Catalent will manufacture and package Inbrija for Acorda. As part of the deal, Catalent will absorb all Acorda employees who work at the Chelsea facility, and certain Acorda employees at the company's Waltham, Massachusetts facility.Acorda also announced a corporate restructuring to reduce costs and focus its resources on Imbrija. In addition to the associates who will transition to Catalent, Acorda is reducing its combined Ardsley, Waltham and field headcount by approximately 16% through a reduction in force.Acorda also said it entered into an at-the-market offering agreement with H.C. Wainwright & Co., for offering common stock having an aggregate value of up to $15.25 million.Acorda shares jumped 59.91% to $6.78 in premarket trading Wednesday.Morphosys, Incyte Announce Canadian Regulatory Submission For Blood Cancer Combo Treatment Morphosys Ag (NASDAQ: MOR) and Incyte Corporation (NASDAQ: INCY) said Health Canada has accepted the new drug submission for tafasitamab, an anti-CD19 antibody, in combination with Bristol-Myers Squibb Co's (NYSE: BMY) Revlimid for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.Incyte has exclusive commercialization rights for tafasitamab outside of the U.S. and, if approved, Incyte will hold the marketing authorization for tafasitamab in Canada.Travere Gets Orphan Drug Designation For Sparsentan In Rare Kidney Disorder Travere announced that the FDA has granted orphan drug designation to sparsentan for the treatment of IgA nephropathy, a rare kidney disorder that causes end-stage kidney disease. Sparsentan is an investigational product candidate currently being evaluated for the treatment of IgAN, as well as focal segmental glomerulosclerosis in pivotal Phase 3 clinical trials that are expected to report topline data from interim proteinuria assessments in 2021.DermTech's Non-invasive Melanoma Genomic Test Recommended by National Comprehensive Cancer Network DermTech said non-invasive genomic patch testing for melanoma, like DermTech's pigmented lesion assay, has received a recommendation from the National Comprehensive Cancer Network. The recommendation indicates that there is uniform NCCN consensus that the intervention is appropriate. The NCCN Clinical Practice Guidelines in Oncology for cutaneous melanoma recognize the use of noninvasive genomic patch testing to help guide biopsy decisions for cutaneous melanoma.The stock gained 12.46% to $41.61 in after-hours trading.Amgen In-licenses Autoimmune Disorder Programs For Over $240M Amgen, Inc. (NASDAQ: AMGN) executed a license and collaboration agreement with EVOQ Therapeutics for the discovery and development of novel drugs for autoimmune disorders. Under the terms of the agreement, Amgen and EVOQ will collaborate on preclinical development and Amgen will be responsible for clinical development and commercialization.In exchange for exclusive rights to selected autoimmune programs, Amgen will make upfront and milestone payments potentially totaling more than $240 million, as well as pay royalties on sales of resulting therapies.Mersana Shares Gain On Insider Buying Mersana Therapeutics Inc (NASDAQ: MRSN) shares gained after a filing with the SEC revealed that Andrew Hack, a member of the board, bought 250,000 shares in the company.The stock added 7.34% to $19.45 in after-hours trading.Preannouncements Ahead of the presentation at the JPMorgan Health Conference Bausch Health Companies Inc (NYSE: BHC) said it expects fourth-quarter revenues to be greater than $2.20 billion. For the full year of 2020, the company expects to report revenues above the high-end of its revenue guidance range of $7.8 billion-$8 billion.Analysts, on average, estimate expect revenues of $2.12 billion for the fourth quarter and $7.94 billion for the full year.The company also guided to strong adjusted EBITDA.In after-hours trading, the stock rose 5.67% to $24.80.Neuronetics Inc (NASDAQ: STIM) preannounced fourth-quarter revenues of $15 million to $15.5 million, ahead of the guidance of $13 million and $13.5 million. For the full year, revenues are estimated between $48.7 million and $49.2 million. The consensus estimates call for revenues of $13.24 for the fourth quarter and $46.93 for the full year.The stock rallied 14.82% to $13.40 in after-hours trading.Clearpoint Neuro Inc (NASDAQ: CLPT) preannounced above-consensus revenues for the fourth quarter and full year.The stock was up 3.43% to $15.99 in after-hours trading.Offerings Provention Bio Inc (NASDAQ: PRVB) said it has commenced an underwritten public offering of 6 million shares of its common stock. All of the shares to be sold in the offering are to be sold by the company.The stock fell 10.03% to $17.50 in after-hours trading.Affimed NV (NASDAQ: AFMD) announced the commencement of an underwritten public offering of its common shares. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering, the company added.In the after-hours session, the stock slipped 7.85% to $6.10.See more from Benzinga * Click here for options trades from Benzinga * The Daily Biotech Pulse: GSK, Vir To Start COVID-19 Antibody Study, Novartis In-Licenses BeiGene's Cancer Drug, Earnings Preannouncements Continue * The Week Ahead In Biotech (Jan 10-16): Expect Stocks To Move As J.P. Morgan Healthcare Conference Kicks Off(C) 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    View More →
  • Amgen To Showcase Next Frontier Of Innovation In Lung Cancer Therapies At WCLC 2020

    Amgen (NASDAQ:AMGN) today announced new data from its oncology pipeline in lung cancer will be presented during the 2020 World Conference on Lung Cancer (WCLC) hosted by the International Association for the Study of Lung Cancer taking place virtually from Jan. 28-31, 2021.

    View More →
  • Gilead, Biogen Lead Biotechs That ‘Need to Do Deals’ for Growth

    (Bloomberg) -- Biotech mergers should pick up steam this year as cash-rich companies whose shares stumbled through 2020 -- like Amgen Inc. and Gilead Sciences Inc. -- look to replenish wavering pipelines.The first two weeks of the year already produced four large tie-ups in health care, and the JPMorgan Healthcare Conference, which kicked off Monday, has typically lent itself to deal news. Wall Street’s anticipation comes as a bevy of heavyweights need to refill their portfolios ahead of expiring patents and emerging competition.“A lot of the big guys, including the pharmaceuticals and not just the biotechs, need to do deals,” BNP Paribas Asset Management portfolio manager Christian Fay said in an interview. “2021 will be better for biopharma deals for sure.”A basket of stocks of the two companies plus Biogen Inc. has fallen 4% since the start of 2020, compared with the 31% gain in the broader Nasdaq Biotech Index.Investors had pushed many of the giants aside last year as they flocked to more innovative smaller companies or some involved in quashing the Covid-19 pandemic. Stock pickers and analysts now see more deals ahead after AstraZeneca Plc’s $39 billion purchase of Alexion Pharmaceuticals Inc.Here are some companies that analysts and investors expects to strike deals in 2021:BiogenHaves: Biogen’s multiple sclerosis and spinal muscular atrophy drugs present a solid base of sales. Potential approval of its experimental Alzheimer’s disease medicine by a March decision date is key after management put “all of their eggs in aducanumab and not building their pipeline,” Fay said.Needs: The company is starved for growth with analysts expecting drug sales to decline over the next two years after a blow to its blockbuster multiple sclerosis drug Tecfidera. Wall Street isn’t sold on whether its $3 billion pact with Sage Therapeutics Inc. will have a near-term impact. Biogen could take on debt to make a deal, but the question is whether it re-rates the stock, Mizuho analyst Salim Syed said. “People are trying to understand whether the equity story gets better if they make a deal,” he said.Stock performance in 2020: -17%AmgenHaves: It delivered some promising pipeline results including data from cancer therapy sotorasib in 2020. Sales for copycat drugs of competitors’ medicines are worth watching with Goldman Sachs highlighting the company among those “best positioned to capitalize on bispecifics.”Needs: Its cardiology business needs a boost after the company terminated a Cytokinetics Inc. partnership for a heart-failure drug. After some underwhelming results from a catalyst-heavy 2020 left the stock lower for the year, Wall Street asked what’s left for shares ahead of a potential rotation out of the $138 billion biotech.“We have deep pockets but short arms, and we’ll dig in for the right opportunities as we have over the past two years,” Amgen CEO Robert Bradway said at the JPMorgan conference Monday. The company doesn’t want to “chase valuations” that could make the biotech’s shareholders lose, he said.Stock performance in 2020: -4.6%Merck & Co.Haves: Merck’s juggernaut cancer drug Keytruda is expected to top $20 billion in annual sales by 2023, according to data compiled by Bloomberg, showing it’s not in a crunch to pull the trigger on deals. The company has been active in striking pacts, buying closely held OncoImmune for $425 million in cash.Needs: Many on Wall Street see Merck leaning further into cancer technologies as it faces patent risks by the end of the decade. It “will be in focus” given the expected completion of its Organon spinoff in the second-quarter, which will leave it flush with $8 billion to $9 billion in a special dividend, Goldman’s Asad Haider wrote. Merck is “actively looking across the entire spectrum of assets to create the strongest portfolio,” the company said in a statement Monday.Stock performance in 2020: -10%Pfizer Inc.Haves: Pfizer’s ability to get a Covid vaccine to market in record time was “nothing short of remarkable,” RBC Capital said. Deployment of the shots adds to Pfizer’s strong portfolio of blockbusters like Ibrance for breast cancer and blood thinner Eliquis with total drug sales expected to top $50 billion this year, data compiled by Bloomberg show.Needs: Still, Pfizer could string smaller deals together to beef up its drug pipeline, BNP Paribas’s Fay said. After a setback for Ibrance, the company could look to bolster its cancer drug portfolio, Jefferies health specialist Jared Holz said. A bigger takeout or more bolt-on acquisitions are likely needed to win over investors as it aims to backfill key patent losses in the medium term.Stock performance in 2020: -0.9%Vertex Pharmaceuticals Inc.Haves: Vertex’s cystic fibrosis concentration has made it one of the most successful biotechs of the past five years. Trikafta is expected to rack up $6.8 billion in sales by 2023. The relative pure play company helps make it “very attractive” ahead of key data readouts in 2021, said Amy Kong, chief investment officer of Barrett Asset Management.Needs: The company is in prime position to strike deals, with $6.2 billion in cash on hand and the need to “become a growth stock again,” Loncar Investments Chief Executive Officer Brad Loncar said. He sees a takeout of partner Crispr Therapeutics AG making “a lot of sense” for its gene-editing technology. At the JPMorgan conference, Vertex CEO Reshma Kewalramani said the company is interested in mid- and late-stage assets and technologies to expand its toolkit.Stock performance in 2020: +7.9%Gilead SciencesHaves: Rapid development of Covid-19 therapeutic Veklury, the brand name for remdesivir, was estimated to bring about $2.8 billion in sales for 2020. Those sales, paired with recent purchases of cancer drug developers Immunomedics Inc. and Forty Seven Inc. and sales growth for its HIV franchise, have been key focuses for bulls.Needs: A restructured partnership with Galapagos NV and a 2017 acquisition of Kite Pharma, the maker of CAR-T cancer therapy Yescarta, have turned up the pressure on Gilead to get deals right. Its shares limped through the end of 2020 after the pair of takeouts and success for a Covid-19 therapy failed to offset broader concerns over its future.Stock performance in 2020: -10%For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.

    View More →
  • Amgen To Achieve Carbon Neutrality By 2027

    Amgen (NASDAQ: AMGN) today announced the launch of a new seven-year environmental sustainability plan, which includes a commitment to achieve carbon neutrality, while also reducing water use by 40% and waste disposed by 75%.

    View More →
  • Dow Jones Turns Lower On Sen. Manchin Comment While Nasdaq Leads, Hits New High

    The Dow Jones Industrial Average traded slightly lower in today's stock market after the major indexes all hit fresh record highs the day prior.

    View More →
  • Moderna Hires Amgen Executive As Chief Commercial Officer To Bolster Vaccine Marketing

    Moderna Inc (NASDAQ: MRNA), which received the fourth regulatory nod for its investigational coronavirus vaccine with the conditional approval granted Wednesday by the European Union, is leaving no stone unturned in its commercialization efforts.What Happened: Boston, Massachusetts-based Moderna said it has hired biopharma industry veteran Corinne Le Goff as chief commercial officer effective Jan. 19. She will report to CEO Stephane Bancel, the company said."I am thrilled to welcome Corinne to Moderna as our chief commercial officer and to the executive committee. Corinne is joining us at an important time as we launch our COVID-19 vaccine, prepare to start the Phase 3 study of our CMV vaccine and pivot to a commercial stage company," Bancel said in a statement.Related Link: Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates Why It's Important: Le Geoff's appointment comes at a time Moderna has started the rollout of its vaccine candidate in the U.S., Canada, Israel and the EU.Additional authorizations are under review in Singapore, Switzerland and the U.K. Le Goff carries a wealth of experience in roles with large-cap pharma companies such as Amgen, Inc. (NASDAQ: AMGN), Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY), Sanofi SA (NASDAQ: SNY) and Pfizer Inc. (NYSE: PFE).Le Geoff was most recently working as senior vice president and president of the U.S. business organization of Amgen, where she was credited with the valuation and commercial integration of psoriasis medication Otelza. Amgen acquired the drug from Celgene.She was also instrumental in driving the growth of products such as Amgen's cholesterol drug Repatha and migraine drug Aimovig.MRNA Price Action: At last check, Moderna shares were rising 0.52% to $116.87.Related Link: The Daily Biotech Pulse: CureVac COVID-19 Vaccine Deal, Argenx Out-Licenses Neuromuscular Disorder Drug, Xencor's Oncology Collaboration See more from Benzinga * Click here for options trades from Benzinga * EMA Committee Recommends Conditional Approval Of Moderna's Coronavirus Vaccine * The Daily Biotech Pulse: Aerpio Reviews Strategic Options, Hologic Goes Shopping(C) 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    View More →
  • Moderna hires Amgen executive as chief commercial officer

    Shares of Moderna Inc. were down 0.2% in trading on Thursday after the company said it had hired an Amgen executive to run commercial operations as it rolls out the first doses of its COVID-19 vaccine, in the U.S. and elsewhere. Corinne Le Goff, a pharmacist by trade and the former president of the U.S. business at Amgen Inc. , will begin her role as chief commercial officer on Jan. 19, reporting to CEO Stéphane Bancel. Moderna's COVID-19 vaccine is the company's first authorized or approved product, and the company is now tasked with building a commercial enterprise to support the vaccine and any future authorized or approved products. Moderna's stock has rallied 553.2% over the last year, while the S&P 500 is up 15.4%.

    View More →
  • Amgen To Present At The 39th Annual J.P. Morgan Healthcare Conference

    Amgen (NASDAQ:AMGN) will present at the 39th Annual J.P. Morgan Healthcare Conference at 11:50 a.m. PT on Monday, Jan. 11, 2021. Robert A. Bradway, chairman and chief executive officer at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for at least 90 days following the event.

    View More →
  • These 6 Dividend Payers Look Primed for Growth in Earnings—and Payouts

    To find some solid income prospects for 2021, Barron’s looked for nice-yielding stocks that are expected to show good earnings growth for 2020. The results: T. Rowe Price, Best Buy, United Parcel Service, Clorox, and Amgen.

    View More →
  • Meet the 2021 Dogs of the Dow

    The Dow Jones Industrial Average (DJINDICES: ^DJI) gets a lot of criticism from academics and Wall Street professionals, who argue that its 30 stocks aren't really a representative sample of the best stocks in the U.

    View More →